Myasthenia Gravis (MG) is a rare autoimmune neuromuscular disease characterized by muscle weakness and fatigue. It occurs when antibodies disrupt communication between nerves and muscles, impairing normal contraction and relaxation. The course of the disease is typically fluctuating, with symptoms that may worsen suddenly. At any stage, patients are at risk of experiencing a myasthenic crisis, a life-threatening episode of severe respiratory failure that requires urgent medical intervention.
The incidence of MG has been steadily increasing in recent years, showing a bimodal distribution: one peak in young adults, another in individuals over 60 years of age. In addition, about 10% of cases are associated with thymoma, a tumor of the thymus gland.
Approximately 80% of patients with MG have detectable antibodies against the acetylcholine receptor (AChR) at the neuromuscular junction. Another 5% carry antibodies against muscle-specific kinase (MuSK). Both antibody types are pathogenic and highly specific for MG. However, in about 10% of cases, patients test negative for both, yet still respond to immunosuppressive treatment.
Treatment options include cholinesterase inhibitors, immunosuppressive medications, intravenous therapies, surgery (such as thymectomy), and, in selected cases, autologous stem cell transplantation. Despite these therapeutic advances, MG remains an incurable disease, and management continues to focus on controlling symptoms and preventing life-threatening complications.
Rheumatoid Arthritis (RA) affects around 1% of the global population and is a chronic, progressive, and currently incurable autoimmune disease that primarily targets the joints. It is characterized by pain, swelling, stiffness, and inflammation, often accompanied by chronic discomfort and functional impairment, making daily activities difficult.
Early diagnosis is critical to slow disease progression and prevent irreversible joint damage. Several biomarkers are currently used to aid diagnosis and monitoring, including rheumatoid factor (RF), anti-citrullinated peptide antibodies (ACPA)—with anti-cyclic citrullinated peptides (CCP) and anti-mutated citrullinated vimentin (MCV) being the most common—along with 14-3-3 eta protein, anti-carbamylated proteins, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).
Until the late 1990s, treatment options were largely limited to small-molecule disease-modifying antirheumatic drugs (DMARDs) such as methotrexate and sulfasalazine. However, about one-third of patients fail to respond to these first-line therapies. The introduction of biologic agents—including etanercept (Enbrel), infliximab (Remicade), and adalimumab (Humira)—revolutionized treatment for patients unresponsive to methotrexate, significantly broadening therapeutic options.
Despite these advances, a substantial proportion of patients do not achieve adequate disease control, even with biologics. There remains a critical unmet need for therapies with greater efficacy, improved safety profiles, and more convenient routes of administration.
Millions of people worldwide live with type 1 diabetes (T1D), a condition also known as juvenile diabetes or insulin-dependent diabetes. While the vast majority of diabetes cases are type 2, about 5% of patients have type 1, forming an important but often misunderstood minority. Contrary to common belief, T1D is not just a childhood disease—it can develop at any age, in people of all backgrounds, body types, and ethnicities.
T1D is a chronic autoimmune condition in which the pancreas produces little or no insulin. Insulin is the hormone that enables glucose (sugar) to enter cells and provide energy. Without it, blood sugar levels rise dangerously, requiring careful lifelong management.
The exact cause remains unknown. Most evidence suggests the immune system—normally responsible for defending the body against infections—mistakenly attacks and destroys the insulin-producing islet cells of the pancreas. Genetics, viral infections, and environmental triggers are also believed to play a role.
Although there is no cure yet, decades of research have led to major progress in treatment. Today, people with T1D manage the condition through insulin therapy, balanced nutrition, and lifestyle strategies, which help control blood sugar and reduce the risk of complications.
Multiple sclerosis (MS) is a chronic and unpredictable neurological disease that can cause a wide variety of symptoms, which may appear suddenly, improve, and then return over time—sometimes within days, other times after months or even years. Although MS is most often diagnosed in young adults, it can occur at any age.
The impact of MS varies greatly from person to person. Some individuals experience only mild symptoms and may not require treatment, while others face significant challenges with mobility and daily activities.
MS develops when the immune system mistakenly attacks the nervous system. More specifically, it targets myelin, the protective fatty layer that surrounds and insulates nerve fibers. When myelin is damaged, the nerves themselves can become scarred or destroyed. Because nerves control nearly every function of the body, MS can lead to a wide range of symptoms—from vision problems and fatigue to difficulties with coordination, speech, and movement.
The exact cause of MS remains unclear, and ongoing research is working to better understand the triggers of the disease and to develop more effective treatments.
Immune thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening autoimmune thrombotic microangiopathy. It results from a severe deficiency of the ADAMTS13 enzyme, caused by autoantibodies that block its function or accelerate its clearance. Without ADAMTS13, ultra-large von Willebrand factor multimers accumulate and trigger widespread platelet clumping, leading to low platelet counts, hemolytic anemia, and organ damage.
Patients often present with thrombocytopenia, anemia, neurologic symptoms, renal impairment, or fever, though not all signs appear at once. The disease is frequently relapsing, and untreated cases are almost always fatal.
Treatment includes plasma exchange to remove antibodies and restore ADAMTS13, combined with immunosuppressive therapy such as corticosteroids or rituximab. Despite advances, many patients remain at risk of relapse, making long-term monitoring essential.
Celiac disease (CD) is a chronic autoimmune disorder that develops in people with a genetic predisposition. When individuals with the condition eat gluten—a protein found in wheat, rye, and barley—it triggers an abnormal immune response that damages the lining of the small intestine. This damage interferes with nutrient absorption and can cause a wide range of symptoms, including diarrhea, fatigue, weight loss, bloating, and anemia. In children, malabsorption may also affect growth and development. If left untreated, celiac disease can lead to serious long-term health complications.
The condition is relatively common, affecting about 1 in 100 people worldwide, though many remain undiagnosed. This lack of diagnosis leaves individuals at risk of ongoing symptoms and future complications.
CD is believed to arise from a combination of genetic susceptibility, gluten consumption, and environmental triggers. Factors such as infant feeding practices, gastrointestinal infections, or changes in gut bacteria may contribute. In some cases, the disease first appears—or becomes active—after surgery, pregnancy, childbirth, viral infection, or severe emotional stress.
Although certain genetic factors increase risk, they do not guarantee that the disease will develop, suggesting that multiple influences must act together for CD to emerge.
Neuromyelitis optica (NMO)—formerly known as Devic’s disease—and neuromyelitis optica spectrum disorders (NMOSD) are rare, immune-mediated inflammatory conditions of the central nervous system. They are characterized by severe demyelination and axonal injury, predominantly affecting the optic nerves and spinal cord. A key diagnostic marker is the presence of NMO-IgG antibodies, which selectively target aquaporin-4 (AQP4), a water channel protein in the CNS.
Clinically, patients experience acute, often severe attacks that may cause blindness, paraparesis or quadriparesis, along with sensory loss and sphincter dysfunction. The majority follow a relapsing course, with episodes separated by months or years and only partial recovery. Relapses are more common in women, who represent nearly 90% of cases. NMO is also frequently associated with other autoimmune diseases, including systemic lupus erythematosus, Sjögren’s syndrome, and myasthenia gravis.
Although some patients may fully recover from individual episodes, residual neurological deficits are common and often severe. Many eventually develop legal blindness in one or both eyes and/or permanent paraparesis.
Currently, immunosuppressive therapy remains the most effective approach to treatment, though its ability to fully prevent relapses is limited. Ongoing research is aimed at developing more targeted therapies to improve long-term outcomes.
